Science AdvancesGenomicsPeer-reviewed journal article
Cancer-driving mutations are enriched in genic regions intolerant to germline variation
Dimitrios VitsiosiD, Ryan S. DhindsaiD, Dorota MatelskaiD, Jonathan MitchelliD, Xuequing Zou, Joshua ArmeniaiD, Fengyuan HuiD, Quanli WangiD, Ben S. SiddersiD, Andrew Robert HarperiD, Slavé PetrovskiiD
- Citations
- 14
- FWCI
- 1.05
- Field percentile
- top 28%
Abstract
Large reference datasets of protein-coding variation in human populations have allowed us to determine which genes and genic sub-regions are intolerant to germline genetic variation. There is also a growing number of genes implicated in severe Mendelian diseases that overlap with genes implicated in cancer. Here, we hypothesized that mitotically mutable genic sub-regions that are intolerant to germline variation are enriched for cancer-driving mutations. We introduce a new metric, OncMTR, which uses 125,748 exomes in the gnomAD database to identify genic sub-regions intolerant to germline variation but enriched for hematologic somatic variants. We demonstrate that OncMTR can significantly predict driver mutations implicated in hematologic malignancies. Divergent OncMTR regions were enriched for cancer-relevant protein domains, and overlaying OncMTR scores on protein structures identified functionally important protein residues. Finally, we performed a rare variant, gene-based collapsing analysis on an independent set of 394,694 exomes from the UK Biobank and find that OncMTR dramatically improves genetic signals for hematologic malignancies. Our web app enables easy visualization of OncMTR scores for each protein-coding gene (https://astrazeneca-cgr-publications.github.io/OncMTR-Viewer/).
- organism: human
- assay: whole-exome sequencing
- research focus: variant effect prediction
- approach: statistical model
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Leveraging cancer mutation data to predict the pathogenicity of germline missense variants
Bushra Haque, David Cheerie, … Gregory Costain·medRxiv·Mar 11, 2024
- No evidence that HLA genotype influences the driver mutations that occur in cancer patients
N. Kherreh, S. Cleary, C. Seoighe·bioRxiv·Apr 21, 2021
- Finding Driver Mutations in Cancer: Elucidating the Role of Background Mutational Processes
A.-L. Brown, M. Li, … A. R. Panchenko·bioRxiv·Apr 1, 2019
- Characterizing and comparing missense variants in monogenic disease and in cancer
Yizhou Yin, John Moult·bioRxiv·Jan 30, 2019
- Germline determinants of the somatic mutation landscape in 2,642 cancer genomes
Lauri A. Aaltonen, Federico Abascal, … Johann Sebastian De Bono·NaturePeer-reviewed·Feb 5, 2020
- Case-control analysis identifies shared properties of rare germline variation in cancer predisposing genes
Mykyta Artomov, Joseph Vijai, … Mark J. Daly·European Journal of Human GeneticsPeer-reviewed·Feb 4, 2019